Law School/Year: Stanford Law School, 1998
College/Year: Carnegie Mellon University, 1993
Commercial, Corporate Business, Technology
During 2008 and 2009, Somaxon encountered numerous delays in the approval process for the New Drug Application for our product Silenor. We were forced to reduce our work force from approximately 40 to five people, and to take various other cash conservation measures while remaining SOX compliant, maintaining our Nasdaq listing and seeking creative financing arrangements. We managed to receive FDA approval for Silenor in March 2010, after which we raised approximately $53 million in a public follow-on offering. We are now making preparations to launch the product in the U.S. market.
I have been general counsel at Somaxon for four years, which involves working with our board of directors and management team to ensure that the company is meeting all legal requirements and managing legal risk across all of its operations. Prior to Somaxon, I worked in-house at Biogen Idec and Elan supporting corporate, commercial and business development activities. Before becoming in-house counsel, I represented life sciences and technology clients as outside counsel in a range of corporate and transactional matters.
I am a member of the California Bar and the Georgia Bar, as well as the San Diego County Bar Association and the Association of Corporate Counsel.
I was born and raised in Pittsburgh, Pa. I have lived in San Diego since 2000, and I currently live in Carmel Valley with my wife Jill and our 6-year-old son Charlie.